- Home
- IDAI vs RSLS Comparison
IDAI vs RSLS Comparison
Compare IDAI & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- RSLS
- Stock Information
- Founded
- IDAI 2016
- RSLS 2002
- Country
- IDAI United States
- RSLS United States
- Employees
- IDAI N/A
- RSLS 18
- Industry
- IDAI Computer Software: Prepackaged Software
- RSLS Medical/Dental Instruments
- Sector
- IDAI Technology
- RSLS Health Care
- Exchange
- IDAI Nasdaq
- RSLS Nasdaq
- Market Cap
- IDAI 4.9M
- RSLS 6.3M
- IPO Year
- IDAI N/A
- RSLS 2007
- Fundamental
- Price
- IDAI $3.16
- RSLS $2.68
- Analyst Decision
- IDAI
- RSLS Hold
- Analyst Count
- IDAI 0
- RSLS 1
- Target Price
- IDAI N/A
- RSLS N/A
- AVG Volume (30 Days)
- IDAI 67.5K
- RSLS 370.1K
- Earning Date
- IDAI 08-12-2025
- RSLS 08-13-2025
- Dividend Yield
- IDAI N/A
- RSLS N/A
- EPS Growth
- IDAI N/A
- RSLS N/A
- EPS
- IDAI N/A
- RSLS N/A
- Revenue
- IDAI $3,054,143.00
- RSLS $7,175,000.00
- Revenue This Year
- IDAI $65.46
- RSLS $52.80
- Revenue Next Year
- IDAI $12.00
- RSLS N/A
- P/E Ratio
- IDAI N/A
- RSLS N/A
- Revenue Growth
- IDAI N/A
- RSLS N/A
- 52 Week Low
- IDAI $1.43
- RSLS $2.23
- 52 Week High
- IDAI $18.75
- RSLS $347.86
- Technical
- Relative Strength Index (RSI)
- IDAI 58.37
- RSLS 42.71
- Support Level
- IDAI $2.80
- RSLS $2.31
- Resistance Level
- IDAI $3.53
- RSLS $2.73
- Average True Range (ATR)
- IDAI 0.36
- RSLS 0.18
- MACD
- IDAI 0.04
- RSLS 0.20
- Stochastic Oscillator
- IDAI 58.33
- RSLS 51.75
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.